Advertisement

TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression

  • Virginie Baylot
  • Sara Karaki
  • Palma RocchiEmail author
Chapter
Part of the Results and Problems in Cell Differentiation book series (RESULTS, volume 64)

Abstract

Prostate cancer (PC) is the second most common cause of cancer-related mortality in men in the western world after lung cancer. Many patients are not candidates for resection given the advanced stage of their cancer. The primary treatment for advanced PC is the castration therapy which supresses the production of androgens, hormone that promotes PC growth. Despite the efficiency of the castration therapy, most patients develop castration resistant disease which remains uncurable. Clearly, novel approaches are required to effectively treat castration resistant PC (CRPC). New strategies that identify the molecular mechanisms by which PC becomes resistant to conventional therapies may enable the identification of novel therapeutic targets that could improve clinical outcome. Recent studies have demonstrated the implication of TCTP’s over-expression in PC and CRPC, and its role in resistance to treatment. TCTP’s interaction with p53 and their negative feedback loop regulation have also been described to be causal for PC progression and invasion. A novel nanotherapy that inhibits TCTP has been developed as a new therapeutical strategy in CRPC. This chapter will highlight the role of TCTP as new therapeutic target in PC, in particular, therapy-resistant advanced PC and report the development of novel nanotherapy against TCTP that restore treatment-sensitivity in CRPC that deserve to be tested in clinical trial.

Keywords

Castration resistant prostate cancer TCTP p53 Antisense oligonucleotides Nanotherapy 

References

  1. Acunzo J, Baylot V, So A, Rocchi P (2014) TCTP as therapeutic target in cancers. Cancer Treat Rev 40(6):760–769CrossRefPubMedGoogle Scholar
  2. Amson R, Pece S, Lespagnol A, Vyas R, Mazzarol G, Tosoni D et al (2012) Reciprocal repression between P53 and TCTP. Nat Med 18:91–99CrossRefGoogle Scholar
  3. Arcuri F, Papa S, Carducci A, Romagnoli R, Liberatori S, Riparbelli MG et al (2004) Translationally controlled tumor protein (TCTP) in the human prostate and prostate cancer cells: expression, distribution, and calcium binding activity. Prostate 60:130–140CrossRefPubMedGoogle Scholar
  4. Baylot V, Andrieu C, Acunzo J, Katsogiannou M, Rocchi P (2010) Nucleic acid targeting TCTP for use in the treatment of cancer. Patent PCT10306447.3Google Scholar
  5. Baylot V, Katsogiannou M, Andrieu C, Taieb D, Acunzo J, Giusiano S et al (2012) Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. Mol Ther 20(12):2244–2256CrossRefPubMedPubMedCentralGoogle Scholar
  6. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154CrossRefPubMedGoogle Scholar
  7. Fusi A, Procopio G, Della Torre S, Ricotta R, Bianchini G, Salvioni R et al (2004) Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori 90:535–546PubMedGoogle Scholar
  8. Gnanasekar M, Thirugnanam S, Zheng GX, Chen AS, Ramaswamy K (2009) Gene silencing of translationally controlled tumor protein (TCTP) by siRNA inhibits cell growth and induces apoptosis of human prostate cancer cells. Int J Oncol 34:1241–1246PubMedGoogle Scholar
  9. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300CrossRefPubMedGoogle Scholar
  10. Kaarbo M, Storm M, Qu S, Wæhre H, Risberg B, Danielsen HE et al (2013) TCTP is an androgen regulated gene implicated in prostate cancer. PLoS One 8(7):e69398CrossRefPubMedPubMedCentralGoogle Scholar
  11. Karaki S et al (2017) Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer. J Control Release 258:1–9Google Scholar
  12. Katsogiannou M, Andrieu C, Baylot V, Baudot A, Dusetti NJ, Gayet O et al (2014) The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets. Mol Cell Proteomics 13(12):3585–3601CrossRefPubMedPubMedCentralGoogle Scholar
  13. McKeage K (2012) Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer. Drugs 72:1559–1577CrossRefPubMedGoogle Scholar
  14. McLeod DG (2003) Hormonal therapy: historical perspective to future directions. Urology 61:3–7CrossRefPubMedGoogle Scholar
  15. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C et al (2005) Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 65:11083–11093CrossRefPubMedGoogle Scholar
  16. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29CrossRefPubMedGoogle Scholar
  17. Theodore C (2004) Hormone therapy for prostate cancer. Bull Cancer 91:69–74PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Virginie Baylot
    • 1
  • Sara Karaki
    • 2
    • 3
    • 4
    • 5
  • Palma Rocchi
    • 2
    • 3
    • 4
    • 5
    Email author
  1. 1.Division of Oncology, Departments of Medicine and PathologyStanford University School of MedicineStanfordUSA
  2. 2.UMR 1068, Inserm, CRCMMarseilleFrance
  3. 3.Institut Paoli-CalmettesMarseilleFrance
  4. 4.Aix-Marseille UniversitéMarseilleFrance
  5. 5.CNRSMarseilleFrance

Personalised recommendations